Natera, Inc. $NTRA Shares Acquired by CI Investments Inc.

CI Investments Inc. raised its stake in Natera, Inc. (NASDAQ:NTRA) by 6.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 54,146 shares of the medical research company’s stock after acquiring an additional 3,343 shares during the period. CI Investments Inc.’s holdings in Natera were worth $8,716,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently made changes to their positions in the company. Sound Income Strategies LLC boosted its position in shares of Natera by 95.7% in the 3rd quarter. Sound Income Strategies LLC now owns 225 shares of the medical research company’s stock valued at $39,000 after purchasing an additional 110 shares during the period. Quent Capital LLC purchased a new stake in Natera in the third quarter valued at approximately $46,000. Hilltop National Bank boosted its holdings in shares of Natera by 59.8% in the third quarter. Hilltop National Bank now owns 310 shares of the medical research company’s stock valued at $50,000 after acquiring an additional 116 shares during the period. N.E.W. Advisory Services LLC boosted its holdings in shares of Natera by 256.8% in the second quarter. N.E.W. Advisory Services LLC now owns 314 shares of the medical research company’s stock valued at $53,000 after acquiring an additional 226 shares during the period. Finally, Blue Trust Inc. grew its position in shares of Natera by 23.1% during the third quarter. Blue Trust Inc. now owns 431 shares of the medical research company’s stock worth $69,000 after acquiring an additional 81 shares during the last quarter. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Natera News Roundup

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Signatera is being highlighted as a primary growth driver for Natera’s oncology business, supporting revenue momentum and investor optimism about recurring MRD testing demand. Signatera Oncology Test Drives Natera’s (NTRA) Growth
• Positive Sentiment: Management presented at TD Cowen’s healthcare conference; the transcript emphasizes commercial progress across oncology (Signatera), reproductive health and transplant products, reinforcing the narrative behind recent revenue beats. Natera Presents at TD Cowen 46th Annual Health Care Conference Transcript
• Positive Sentiment: Coverage noting why the stock traded up ties the move to the company’s recent operational beats and growth commentary, which can amplify buying interest on upside news. Natera (NTRA) Stock Trades Up, Here Is Why
• Neutral Sentiment: Morgan Stanley trimmed its price target from $265 to $250 but kept an Overweight rating — a modestly negative signal on price scope but still reflects continued analyst confidence. Morgan Stanley Lowers Price Target
• Neutral Sentiment: MarketBeat/analyst notes show a consensus “Moderate Buy” and a cluster of raised targets from other firms, indicating mixed but generally constructive analyst sentiment that could limit downside. NTRA MarketBeat Summary
• Negative Sentiment: Insider selling: CEO Steven Chapman and longtime insider Solomon Moshkevich sold shares in early March (transactions near $200/sh), which can weigh on sentiment even if the trades appear to be routine liquidity. Natera Insider Sells $599,550.00 in Stock

Insiders Place Their Bets

In other Natera news, CEO Steven Leonard Chapman sold 3,950 shares of the stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $200.02, for a total value of $790,079.00. Following the completion of the transaction, the chief executive officer owned 156,607 shares in the company, valued at approximately $31,324,532.14. This represents a 2.46% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider John Fesko sold 3,594 shares of the business’s stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $231.02, for a total transaction of $830,285.88. Following the sale, the insider owned 178,081 shares in the company, valued at $41,140,272.62. The trade was a 1.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 367,669 shares of company stock valued at $85,584,453 in the last three months. 5.63% of the stock is owned by corporate insiders.

Natera Stock Down 1.9%

Shares of Natera stock opened at $203.03 on Thursday. The firm has a market cap of $28.78 billion, a price-to-earnings ratio of -132.70 and a beta of 1.65. Natera, Inc. has a 52-week low of $125.38 and a 52-week high of $256.36. The company’s 50-day simple moving average is $224.59 and its 200-day simple moving average is $204.76.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Thursday, February 26th. The medical research company reported $0.35 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.81. The company had revenue of $665.50 million for the quarter, compared to analyst estimates of $600.68 million. Natera had a negative return on equity of 15.28% and a negative net margin of 9.03%.During the same quarter in the previous year, the company earned ($0.41) EPS. Equities research analysts anticipate that Natera, Inc. will post -1.49 EPS for the current year.

Analysts Set New Price Targets

NTRA has been the subject of a number of recent research reports. Stephens increased their price target on shares of Natera from $197.00 to $235.00 and gave the stock an “overweight” rating in a research note on Thursday, November 13th. Wells Fargo & Company upped their target price on shares of Natera from $205.00 to $215.00 and gave the company an “equal weight” rating in a report on Friday, February 27th. Evercore increased their target price on shares of Natera from $190.00 to $250.00 and gave the stock an “outperform” rating in a research note on Friday, November 7th. Robert W. Baird boosted their price target on Natera from $239.00 to $257.00 and gave the company an “outperform” rating in a research report on Friday, February 27th. Finally, JPMorgan Chase & Co. upped their price objective on Natera from $250.00 to $260.00 and gave the company an “overweight” rating in a research note on Monday, December 15th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Natera currently has a consensus rating of “Moderate Buy” and an average target price of $253.47.

Natera Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.